Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
JSPR · NASDAQ · Biological Products, (No Diagnostic Substances)
$8.69−2.06 (−19.16%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Jasper Therapeutics (JSPR) · oqro.io/stocks/JSPR · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 16, 2026
Armistice Capital, LLC now owns 10.0% of JSPR as a passive investorSource5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 13, 2026
Affinity Asset Advisors, LLC now owns 5.6% of JSPR as a passive investorSource5%+ stake · Stake as of Sep 30, 2026 · Filed Oct 28, 2026
BANK OF AMERICA CORP /DE/ now owns 6.4% of JSPR as a passive investorSourceInsider trade · Traded Sep 22, 2025 · Filed Sep 24, 2025
CEO purchased ~$100K of JSPR shares in the open marketSourceInsider trade · Traded Sep 22, 2025 · Filed Sep 24, 2025
Director purchased ~$100K of JSPR shares in the open marketSourceInsider trade · Traded Sep 22, 2025 · Filed Sep 24, 2025
Director purchased ~$100K of JSPR shares in the open marketSourceInsider trade · Traded Sep 22, 2025 · Filed Sep 24, 2025
Director purchased ~$49K of JSPR shares in the open marketSourceInsider trade · Traded Dec 12, 2024 · Filed Dec 13, 2024
Officer sold ~$20K of JSPR shares in the open marketSource